Vivo Capital, LLC Q2 2018 Filing
Filed August 10, 2018
Portfolio Value
$776.1B
Holdings
40
Report Date
Q2 2018
Filing Type
13F-HR
All Holdings (40 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ASNDAscendis Pharma | 2,166,832 | $144.1B | 18.57% | |
| 2 | —Biohaven Pharmaceutical Holding Company Ltd | 2,049,545 | $81.0B | 10.44% | |
| 3 | —Kadmon Holdings (KDMN) | 10,454,545 | $68.9B | 8.88% | |
| 4 | CDXSCodexis, Inc. | 3,054,825 | $44.0B | 5.67% | |
| 5 | ACRSAclaris Therapeutics | 1,647,214 | $32.9B | 4.24% | |
| 6 | —Menlo Therapeutics | 4,011,236 | $32.6B | 4.20% | |
| 7 | APLSApellis Pharmaceuticals, Inc. | 1,456,499 | $32.0B | 4.13% | |
| 8 | 1T7Tricida, Inc. | 991,711 | $29.7B | 3.82% | |
| 9 | FIXXEURHomology Medicines, Inc. | 1,409,742 | $28.8B | 3.71% | |
| 10 | MEIPUSDMEI Pharma Inc (NAS) | 6,600,660 | $26.0B | 3.35% | |
| 11 | ARWRArrowhead Pharmaceuticals In | 1,900,000 | $25.8B | 3.33% | |
| 12 | CLDNEUREiger BioPharmaceuticals | 1,791,257 | $21.9B | 2.82% | |
| 13 | AMRSEURAmyris, Inc. | 2,826,711 | $18.1B | 2.33% | |
| 14 | MDGLMadrigal Pharmaceuticals Inc | 62,220 | $17.4B | 2.24% | |
| 15 | KALAKala Pharmaceuticals, Inc. | 1,043,020 | $14.3B | 1.85% | |
| 16 | —Nabriva Therapeutics Plc | 4,074,190 | $14.2B | 1.83% | |
| 17 | —Obseva SA | 925,000 | $14.0B | 1.80% | |
| 18 | CBAYUSDCymabay Therapeutics inc | 906,000 | $12.2B | 1.57% | |
| 19 | —Strongbridge Biopharma plc | 1,918,132 | $11.5B | 1.48% | |
| 20 | SELBUSDSelecta Biosciences, Inc. | 780,601 | $10.3B | 1.33% | |
| 21 | —Soleno Therapeutics, Inc. | 4,359,683 | $10.2B | 1.31% | |
| 22 | DCPHEURDeciphera Pharmaceuticals In | 252,942 | $10.0B | 1.28% | |
| 23 | GLMDGalmed Pharmaceuticals Ltd | 792,707 | $9.4B | 1.22% | |
| 24 | —Zymeworks Inc | 620,134 | $9.2B | 1.18% | |
| 25 | —Sierra Oncology, Inc | 2,438,270 | $7.2B | 0.93% | |
| 26 | —Genocea Biosciences Inc(NMS) | 8,180,000 | $7.0B | 0.90% | |
| 27 | AUPHAurinia Pharmaceuticals Inc. | 1,213,290 | $6.8B | 0.88% | |
| 28 | RGNXRegenxbio Inc. | 82,403 | $5.9B | 0.76% | |
| 29 | ZLABZai Lab LTD | 231,010 | $5.4B | 0.69% | |
| 30 | —Zogenix, Inc. | 105,000 | $4.6B | 0.60% | |
| 31 | —Foamix Pharmaceuticals Ltd. | 855,000 | $4.3B | 0.55% | |
| 32 | —BioPharmX Corporation | 16,128,515 | $3.6B | 0.46% | |
| 33 | KNSAKiniksa Pharmaceuticals-A | 186,073 | $3.2B | 0.42% | |
| 34 | VRNAVerona Pharma Plc | 1,492,951 | $2.8B | 0.36% | |
| 35 | —Trevena, Inc. | 1,728,000 | $2.5B | 0.32% | |
| 36 | KALVKalVista Pharmaceuticals, Inc. | 300,325 | $2.4B | 0.31% | |
| 37 | —Agile Therapeutics, Inc. | 1,513,975 | $742.0M | 0.10% | |
| 38 | —Akari Therapeutics Plc | 345,850 | $674.0M | 0.09% | |
| 39 | —Sunesis Pharmaceuticals, Inc. | 195,474 | $414.0M | 0.05% | |
| 40 | —Soleno Therapeutics, Inc. | 188,772 | $79.0M | 0.01% |